Bullish & Foolish
Full IBO fundamentals All 466 on the Survival Watch

IBOImpact BioMedical, INC.

Is Impact BioMedical struggling financially?

Yes, by its own account. Impact BioMedical told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

0/100

Critical

Sector
Biotech/Pharma
Market cap
$51.8M
Source filing
10-Q 12 May 2026
Balance sheet
30 Jun 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash burned over the last 12 months

$2.3M

What Impact BioMedical told the SEC

…statements the Company has incurred operating losses as well as negative cash flows from operating activities over the past two years. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. These consolidated financial statements do not include any adjustments to the specific amounts and classifications…

Impact BioMedical, INC., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 789.2% share-count increase The company issued stock. Each share now owns 88.8% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt